Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: May 31, 2022
Understanding
and
measuring
the
individual
level
of
immune
protection
its
persistence
at
both
humoral
cellular
levels
after
SARS-CoV-2
vaccination
is
mandatory
for
management
booster
campaign.
Our
prospective
study
was
designed
to
assess
immunogenicity
BNT162b2
mRNA
vaccine
in
triggering
response
healthcare
workers
up
12
months
initial
vaccination,
with
one
additional
boosting
dose
between
6
months.
Nature Communications,
Journal Year:
2022,
Volume and Issue:
13(1)
Published: Aug. 8, 2022
Abstract
Understanding
the
impact
of
age
on
vaccinations
is
essential
for
design
and
delivery
vaccines
against
SARS-CoV-2.
Here,
we
present
findings
from
a
comprehensive
analysis
multiple
compartments
memory
immune
response
in
312
individuals
vaccinated
with
BNT162b2
SARS-CoV-2
mRNA
vaccine.
Two
vaccine
doses
induce
high
antibody
T
cell
responses
most
individuals.
However,
recognition
Spike
protein
Delta
Omicron
variants
less
efficient
than
that
ancestral
Wuhan
strain.
Age-stratified
analyses
identify
group
low
responders
where
≥60
years
are
overrepresented.
Waning
cellular
observed
30%
vaccinees
after
6
months.
does
not
influence
waning
these
responses.
Taken
together,
while
old
take
longer
to
acquire
vaccine-induced
immunity,
they
develop
more
sustained
acquired
immunity
at
months
post-vaccination.
A
third
dose
strongly
boosts
older
strain,
variants.
CoronaVac
is
an
inactivated
SARS-CoV-2
vaccine
approved
by
the
World
Health
Organization
(WHO).
Previous
studies
reported
increased
levels
of
neutralizing
antibodies
and
specific
T
cells
2
4
weeks
after
two
doses
CoronaVac;
these
were
significantly
reduced
at
6
to
8
months
doses.
Here,
we
report
effect
a
booster
dose
on
anti-SARS-CoV-2
immune
response
generated
against
variants
concern
(VOCs),
Delta
Omicron,
in
adults
participating
phase
III
clinical
trial
Chile.
Volunteers
immunized
with
4-week
interval
received
same
between
24
30
second
dose.
Neutralization
capacities
cell
activation
VOCs
Omicron
assessed
We
observed
significant
increase
also
rise
anti-SARS-CoV-2-specific
CD4
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2022,
Volume and Issue:
unknown
Published: March 21, 2022
Multiple
COVID-19
vaccines,
representing
diverse
vaccine
platforms,
successfully
protect
against
symptomatic
cases
and
deaths.
Head-to-head
comparisons
of
T
cell,
B
antibody
responses
to
vaccines
in
humans
are
likely
be
informative
for
understanding
protective
immunity
COVID-19,
with
particular
interest
immune
memory.
Here,
SARS-CoV-2-spike-specific
Moderna
mRNA-1273,
Pfizer/BioNTech
BNT162b2,
Janssen
Ad26.COV2.S
Novavax
NVX-CoV2373
were
examined
longitudinally
6
months.
100%
individuals
made
memory
CD4
+
cells,
cTfh
CD4-CTL
highly
represented
after
mRNA
or
vaccination.
induced
comparable
CD8
cell
frequencies,
though
cells
only
detectable
60-67%
subjects
at
was
not
the
strongest
immunogen
by
any
measurement,
relatively
stable
over
A
differentiating
feature
immunization
a
high
frequency
CXCR3
cells.
vaccinees
had
substantial
declines
neutralizing
antibodies,
while
comparatively
These
results
these
detailed
immunological
evaluations
may
also
relevant
design
insights
other
pathogens.
Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: May 31, 2022
Understanding
and
measuring
the
individual
level
of
immune
protection
its
persistence
at
both
humoral
cellular
levels
after
SARS-CoV-2
vaccination
is
mandatory
for
management
booster
campaign.
Our
prospective
study
was
designed
to
assess
immunogenicity
BNT162b2
mRNA
vaccine
in
triggering
response
healthcare
workers
up
12
months
initial
vaccination,
with
one
additional
boosting
dose
between
6
months.
